Rentschler Biopharma SE appoints Henning Gerschewski as Vice President Manufacturing Science and Technology

Laupheim, Germany, December 20, 2018 – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that Henning Gerschewski (44) will join the company as Vice President Manufacturing Science and Technology, effective January 01, 2019. He will head a highly experienced team of senior scientists with the goal of ensuring technical leadership in process development and technology transfer activities. He will drive innovation and implement best practices and solutions for drug substance manufacturing, working with Rentschler Biopharma’s production, development and quality teams. Mr. Gerschewski has more than 15 years of experience in cell culture cultivation, downstream processing as well as technology transfers.

“Henning Gerschewski is the missing puzzle piece to fully complete and head our team of highly qualified scientists. We warmly welcome him back to the Rentschler family, where he will lead the translation of our strategy into new technology opportunities and applications,” commented Dr. Ralf Otto, COO of Rentschler Biopharma SE. “With Henning running our Manufacturing Science and Technology department, our clients’ needs will be perfectly matched with market trends and Rentschler Biopharma’s advanced technologies to deliver robust processes and high-quality products. His exceptional knowledge and track record in process and technology transfer activities further strengthen our technology leadership position within the CDMO market.”

“I am very excited to be returning to Rentschler Biopharma. The biopharmaceutical industry requires first-in-class development and manufacturing processes to enable the production and launch of innovative therapies. This is our contribution to helping patients with serious or rare diseases. I truly believe that there is no such thing as an impossible to manufacture medicine and will do my best to overcome any current technological limitations. I am looking forward to providing high-quality service to our clients and, together with the excellent team at Rentschler Biopharma, delivering on our mission to translate medical research into outstanding biopharmaceuticals. This is what makes a difference and positions us as the CDMO of choice today and for the future.”

Prior to joining Rentschler Biopharma, Mr. Gerschewski worked in various roles of increasing responsibility at Boehringer Ingelheim, most recently as Director Process Transfer and Technical Operations in Fremont, CA, USA. Between 2002 and 2006, he was Team Leader Downstream Processing at Rentschler Biopharma. Mr. Gerschewski has a degree in bioprocess engineering from the University of Applied Sciences in Flensburg, Germany.

About Rentschler Biopharma SE

Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO), focused exclusively on clients' projects. Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer optimal solutions across the entire value chain, the company has entered into a strategic alliance for formulation development with Leukocare AG and into a strategic partnership for fill & finish with Rentschler Fill Solutions GmbH. Rentschler Biopharma is a family-owned company employing more than 850 people. For further information, please visit www.rentschler-biopharma.com.